Peripheral Neuropathy in Children With Chronic Kidney Disease: Are We Looking Enough?

Ahibhushan Sonbhadra, Bandi V. Chaitthanya Reddy, Arushi G. Saini, Kara Tiewsob, Pradip Paria, Shivam Kesavan, Renu Suthar, Lesa Dawman, Savita Attri

Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, Department of Pediatrics, Pediatric Neurology Unit, Postgraduate Institute of Medical Education and Research, Chandigarh, Department of Pediatrics, Pediatric Nepliology Unit, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Abstract

Background: Peripheral neuropathy in chronic kidney disease (CKD) is the most common neurological complication. We aimed to look at the prevalence and patterns of neuropathy in children with CKD. Methods: This cross-sectional study was conducted over 1 year in children with CKD, stage III and above. Nerve conduction studies (NCS) were performed as per standard protocols using surface electrodes on the muscles and by supramaximal stimulation of the corresponding nerves. Presence of electrophysiological abnormalities in the absence of clinical symptoms or signs was considered as subclinical neuropathy. Results: Nearly 45 children were evaluated. The majority were males (n = 39, 86.7%). The mean age was 7.9 ± 3 years (range 2–14). The mean estimated glomerular filtration rate (GFR) at enrolment was 23.3 ± 14.6 mL/min/1.73 m^2 (range 5–67). The majority of children were in stage III (n = 19, 42%), followed by stages V (n = 15, 33%) and IV (n = 11, 25%). There was no evidence of clinical neuropathy; 13 children (29%) showed subclinical neuropathy. All the nerves had an axonal pattern of involvement. Motor polyneuropathy was most common type of peripheral neuropathy. The commonest nerves involved were tibial and common peroneal nerves. There were no biochemical or clinical predictors of neuropathy in our cohort. Conclusion: The prevalence of subclinical neuropathy is high in children with CKD, stage III and above. Axonal motor polyneuropathy is the predominant pattern. Electrophysiological assessment of nerve function should be routinely done in children with advanced stages of CKD to prevent chronic complications.

Keywords: Children, chronic kidney disease, peripheral neuropathy, renal disease, subclinical neuropathy, uremic neuropathy

INTRODUCTION

Peripheral neuropathy in chronic kidney disease (CKD), also known as uremic neuropathy, is one of the common neurological complication associated with a disorder. It affects up to 70% of pre-dialysis and 90% of dialysis patients.[1-3] It usually occurs with a glomerular filtration rate (GFR) <12 mL/min/1.73 m^2.[4] The pathogenesis is complex and multifactorial, including altered metabolic milieu. It affects both sensory and motor nerves. Neuropathy is considered an indication to initiate renal replacement therapy, especially when there is a loss of motor function. The neuropathy commonly begins as a distal, symmetrical, loss of sensation to pinprick and vibration in the lower limbs, with or without diminished reflexes, and may lead to motor weakness and muscle atrophy.[3]

This comorbidity has received less attention in pediatric CKD compared to chronic diseases such as type 1 diabetes.[5-7] In the absence of standardized guidelines and protocols for evaluation, peripheral neuropathy in children with CKD is probably under-recognized, especially in resource-constraint settings. Identification of peripheral neuropathy at an early stage of the disease and the factors predisposing to its development will help in risk stratification and selection of subjects for targeted interventions, thus preventing complications such as ulceration, infection, necrosis, and limb loss. Hence, looking at the burden of CKD in children and lack of studies on peripheral neuropathy in this cohort, we looked at the prevalence and patterns of neuropathy in children with CKD.

METHODOLOGY

This cross-sectional study was conducted over 1 year in the Pediatric Nephrology and Pediatric Neurology units of the Department of Pediatrics at a tertiary care teaching hospital. Institute’s ethics committee approved the study protocol and the departmental review board approved the manuscript. The inclusion criteria were (1) consecutive children of either sex between 2 and 14 years and (2) a diagnosis of CKD stage III–V as per the standard definition.[8] Children with co-existing disorders that may affect the peripheral nerves (such as diabetes, connective tissue disorders, thyroid disorders, coeliac disease) were excluded.

Address for correspondence: Dr. Arushi G. Saini, Department of Pediatrics, Pediatric Neurology Unit, Postgraduate Institute of Medical Education and Research, Chandigarh - 160 012, India. E-mail: doc.arushi@gmail.com

Submitted: 12-Dec-2021 Revised: 26-Jun-2022 Accepted: 04-Apr-2022 Published: 24-Jun-2022

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

DOI: 10.4103/aian.aian_1067_21
disease, etc.), or using medications predisposing to peripheral neuropathy (such as chemotherapy, antiretroviral therapy, antitubercular therapy, or antifungal drugs), or with a family history of peripheral nerve disorders (inherited neuropathies) were excluded. Informed consent was taken from the parents prior to enrollment.

All children were evaluated for the presence of signs and symptoms of neuropathy. Nerve conduction studies (NCS) were performed as per standard protocols using surface electrodes on the muscles and by supramaximal stimulation of the corresponding nerves. At least two motor (median and ulnar in the upper limb, common peroneal and tibial in the lower limbs), and one sensory (ulnar/median in the upper limb and sural in the lower limb) nerves in each of the four extremities were assessed. All four limbs were tested so that no cases of uremic mononeuropathies were missed. Motor conduction studies were measured with surface electrodes on the muscles by supramaximal stimulation of the corresponding nerves. Median and ulnar nerves were stimulated at the wrist and elbow, with motor action potential being recorded over the abductor pollicis brevis and abductor digiti minimi, respectively. Peroneal and tibial nerves were stimulated at the ankle and knee, with motor action potential being recorded over the extensor digitorum brevis and abductor hallucis, respectively. Sensory NCS was performed on the median, ulnar, and sural nerves, with orthodromic stimulation at finger II, finger V, and lateral malleolus, respectively. The sensory action potentials of the median and ulnar nerves was recorded at the wrist and at the lower leg for the sural nerve. Care was taken to keep the room temperature constant during the measurements by prewarming the extremities, if required by heat packs. The values of distal latency, conduction velocities, and amplitudes of compound muscle action potential (CMAP) and sensory nerve action potential (SNAP) were recorded and interpreted using the age-adjusted reference values.\textsuperscript{[9-11]} Peripheral neuropathy was considered when ≥2 abnormal attributes were detected in NCS, with evidence of muscle weakness, diminished ankle reflexes, altered sensation, or autonomic dysfunction.\textsuperscript{[12,13]} For mononeuropathy, these features were considered in any motor or sensory nerve.\textsuperscript{[13]} The subclinical neuropathy (as a subcomponent of asymptomatic neuropathy) was defined as the presence of an NCS abnormality, in the absence of abnormal neurologic examination or symptoms of neuropathy.\textsuperscript{[13]} The neuropathy was graded according to Dyck’s criteria originally proposed for diabetic neuropathy using a combination of nerve studies, clinical examination, and neuropathy symptoms [Table 1].\textsuperscript{[14]}

Statistical analysis was done using the Statistical Package for Social Sciences for Windows version 23 (SPSS Inc., Chicago, IL, USA). Quantitative data is depicted as mean ± standard deviation (SD), while the qualitative data is depicted as demonstrated as frequency and percentage. Independent T-test and Chi-square test or Fisher’s exact tests, as appropriate, were used to compare data between the groups. A $P < 0.05$ was considered statistically significant.

### Results

Nearly 45 children were evaluated during the study period. The majority were males ($n = 39, 86.7\%$). The mean estimated GFR at enrollment was $23.3 ± 14.6 \text{ mL/min/1.73 m}^2$ (range 5–67). The majority of children were in stage III ($n = 19, 42\%$), followed by stages V ($n = 15, 33\%$) and IV ($n = 11, 25\%$). The clinical and demographic characteristics are shown in Table 2.

None of the children with CKD stage III and above had signs or symptoms of peripheral neuropathy. Of these, 13 children (29\%) showed signs of subclinical or asymptomatic neuropathy (stage 1). All the nerves had an axonal pattern. Motor polyneuropathy was the most common pattern of involvement. The commonest nerves involved were tibial and common peroneal nerves [Figure 1]. No clinical and biochemical predictors of peripheral neuropathy were identified in the cohort [Table 3]. The stages of disease ($P = 0.8$), presence of dialysis ($P = 0.7$), and gender ($P = 0.6$) did not predict the presence of neuropathy.

### Discussion

Our study shows that subclinical uremic polyneuropathy is seen in up to one-third of children with CKD stage 3 and above. Being subclinical, the entity is probably unrecognized in children. Hence, NCS-based assessment of nerve function should be routinely done in children with advanced stages of CKD, at least once a year to prevent chronic complications. Children who show electrophysiological abnormalities without any clinical signs or symptoms should undergo prospective screening to evaluate the evolution of clinical uremic neuropathy. Though often insidious, peripheral neuropathy has been considered a source of physical impairment and has reduced the quality of life in CKD secondary to progressive muscle atrophy, weakness, and gait abnormalities.\textsuperscript{[17,18]} Uremic neuropathy

| Table 1: NCS attributes considered in the study\textsuperscript{[15,16]} |
| Abnormal attributes for motor studies were: |
| CMAP amplitude <80% of 2.5 SD |
| Conduction velocity <75% of 2.5 SD below normal for age |
| Distal latency >130% of 2.5 above normal for age |
| Proximal CMAP amplitude <50% of distal CMAP amplitude, and |
| F-wave latency >130% of upper limit of normal for age |
| Abnormal attributes for sensory studies were: |
| SNAP amplitude <80% of 2.5 SD |
| Conduction velocity <75% of 2.5 SD below normal for age |
| Distal latency >130% of 2.5 above normal for age |
| Staging of neuropathy\textsuperscript{(9):} |
| Stage 0 (no neuropathy): Absence of NCS abnormality, abnormal neurologic examination, and symptoms of neuropathy |
| Stage 1 (asymptomatic neuropathy): Presence of NCS abnormality or abnormal neurologic examination or both plus no symptoms of neuropathy |
| Stage 2 (symptomatic neuropathy): Presence of NCS abnormality or abnormal neurologic examination or both plus symptoms of neuropathy |
| Stage 3 (disabling neuropathy): Presence of NCS abnormality or abnormal neurologic examination or both plus disabling symptoms of neuropathy |
in pediatric cohorts varies from 0% to 52%.[19] Diminished motor nerve conduction was seen in a single case in a small cohort of 11 children with CKD, although electromyogram revealed increased polyphagia of motor unit potentials in four cases.[7] A higher prevalence of electrophysiologically defined peripheral neuropathy (52%) was seen in another North Indian cohort of 50 children with CKD.[3] The study included children up to 18 years, thereby with prolonged duration of illness. A higher prevalence (0–59%) of electrophysiologically defined polyneuropathy has been reported in children with more severe stages of CKD (stage IV and V).[7,19] About 19 children in our cohort were in CKD stage III, followed by 15 in CKD stage V. We did not find any effect of the with evidence of muscle weakness stage of CKD on the frequency of neuropathy. The presence of uremic neuropathy is an indication for renal replacement therapy and the development of neuropathy in children already on renal replacement therapy should hint toward ineffectiveness and need to adjust the dose and duration of dialysis.[18] Although earlier reports suggested that some patients with CKD and mild neuropathy may recover completely with adequate dialysis, however, recent studies indicate that improvement in neuropathy, especially in severe cases and with motor-predominant pattern, is uncommon with both hemo- and peritoneal dialysis.[3] In some cases, neuropathy may progress despite dialysis and renal transplantation is considered the only cure for uremic nephropathy. Such extensive data is lacking in children and larger studies are needed to study the serial changes in nerve conduction in children with CKD and the effect of renal replacement therapy in them.

| Table 2: Clinical and demographic characteristics of enrolled children (N=45) |
| --- |
| Characteristics | N (%) |
| Male gender | 39 (86.7%) |
| Age at diagnosis of CKD (m) | 51.1±43.7 (birth-132) |
| Age at enrolment (year) | 7.9±3 (2-14) |
| Duration of CKD (year) | 3.7±3.4 (0.5-12) |
| Estimated GFR at enrolment (mL/min/1.73 m²) | 23.3±14.6 (5-67) |
| Stage of disease | |
| Stage 3 | 19 (42%) |
| Stage 4 | 11 (25%) |
| Stage 5 | 15 (33%) |
| Weight at enrolment (kg) | 19.5±7.8 (8.7-38.2) |
| Height at enrolment (cm) | 113.6±16.7 (76-141.5) |
| Dialysis | 20 (44%) |
| Clinical neuropathy | None |
| Subclinical peripheral neuropathy | 13 (29%) |
| Motor polyneuropathy | 7 (54%) |
| Motor mono-neuropathy | 5 (38%) |
| Tibial nerve | 4 (30%) |
| Peroneal nerve | 1 (8%) |
| Motor and sensory neuropathy | 1 (8%) |
| Sensory | None |
| Involvement of nerves | |
| Tibial | 11/13 (84.6%) |
| Peroneal | 3/13 (23%) |
| Sural | 1/13 (7.6%) |
| Mean amplitude±SD (mV) | |
| Tibial | 9.8±4.7 |
| Common peroneal | 3.4±1.2 |
| Median | 7.4±2.5 |
| Ulnar | 4.9±1.3 |
| Type of subclinical neuropathy | Axonal |
| Mean amplitude±SD (mV) | 13 (29%) |
| Tibial | 4.9±1.3 |
| Common peroneal | 3.3±1.1 |
| Median | 7.8±2.4 |
| Ulnar | 4.5±1.3 |

| Table 3: Association between probable risk factors and presence of subclinical neuropathy |
| --- |
| Subclinical neuropathy | Mean±SD | P |
| Presence | N |
| Age at enrolment (year) | Yes | 13 | 8.5±2.7 | 0.4 |
| No | 32 | 7.7±1.1 |
| Age at diagnosis of CKD (m) | Yes | 13 | 50.8±50.5 | 0.9 |
| No | 32 | 51.2±41.6 |
| Height (cm) | Yes | 13 | 113.6±16.7 | 0.9 |
| No | 32 | 113.1±17.8 |
| Weight (kg) | Yes | 13 | 19.5±7.8 | 0.9 |
| No | 32 | 19.5±7.1 |
| Head circumference (cm) | Yes | 13 | 49.7±7.2 | 0.9 |
| No | 32 | 49.6±7.3 |
| Body mass index (kg/m²) | Yes | 13 | 14.7±1.9 | 0.9 |
| No | 32 | 14.7±1.7 |
| Height for age | Yes | 13 | −3.4±1.5 | 0.1 |
| No | 32 | −2.7±1.4 |
| Weight for age | Yes | 13 | −3.6±1.8 | 0.1 |
| No | 32 | −2.8±1.5 |
| Weight for height | Yes | 7 | −1.2±1.5 | 0.8 |
| No | 21 | −1.4±1.5 |
| Mid arm circumference (cm) | Yes | 13 | 15.9±1.5 | 0.6 |
| No | 32 | 16.2±2.2 |
| Serum Potassium (meq/L) | Yes | 13 | 4.3±0.3 | 0.2 |
| No | 32 | 4.4±0.4 |
| Serum sodium (meq/L) | Yes | 13 | 137.6±3.9 | 0.6 |
| No | 32 | 138.3±4.1 |
| Serum parathormone level | Yes | 13 | 209.7±88.8 | 0.2 |
| No | 32 | 179.6±67.1 |
| Serum vitamin D level | Yes | 13 | 21.2±12 | 0.6 |
| No | 32 | 19.8±9.8 |
| Serum phosphorus level | Yes | 13 | 3.9±0.9 | 0.2 |
| No | 32 | 3.7±0.6 |
| Creatinine | Yes | 13 | 2.9±2.1 | 0.7 |
| No | 32 | 2.8±1.7 |
| Urea | Yes | 13 | 110.3±68.1 | 0.1 |
| No | 32 | 87.6±38.7 |
| Estimated GFR | Yes | 13 | 24.7±17.4 | 0.6 |
| No | 32 | 22.7±13.5 |
Peripheral neuropathy in CKD is classically considered a distal symmetrical, mixed sensorimotor neuropathy. The nerves show both demyelination and axonal degeneration. The subclinical neuropathy in our cohort was axonal motor type and it affected the tibial and peroneal nerves in the lower limbs. Motor-sensory neuropathy was seen in only a single case in our cohort while none had a pure sensory neuropathy. The pathogenesis of uremic neuropathy has been considered a primary axonal degeneration, resulting in secondary segmental demyelination. Understandably, these changes are most severe in the distal ends of the longer nerve fibers of the lower limbs, as also seen in our cohort. Motor NCS is commonly measured in the peroneal nerve. Similar to our study, majority of children with CKD have shown an axonal pattern (80.8%), followed by demyelinating (18.5%). Isolated motor involvement (92.3%) is more common followed by sensorimotor neuropathy (7.6%), as also seen in our cohort. It has been shown that the mean peroneal motor CV decreased significantly in children with mild renal failure, while ulnar motor CV was significantly reduced only when renal failure was advanced. The predominance of isolated motor neuropathy in our study and the one by Yoganathan et al. could be attributed to inclusion of children with “non-diabetic” CKD, and an effect of the duration and severity of CKD in different cohorts.

The pathogenesis of peripheral neuropathy in children with CKD is complex. It has been attributed to the accumulation of uremic toxins such as parathyroid hormone, myoinositol, etc., oxidative free radical damage to the nerves, and electrolyte abnormalities. Specifically, hyperkalemia and hyperphosphatemia can cause chronic depolarization of nerves by disrupting the normal ionic gradient and activating the calcium-mediated processes leading to axonal death. Both these factors were not associated with development of subclinical neuropathy in our cohort. The effect of serum biochemical parameters has not been found significant on the causation of uremic neuropathy in other studies as well. A possible reason for this could be the rapid correction of transient hyperkalemia with dialysis, thus causing lesser disruption of normal ionic gradients and lesser activation of calcium-mediated neurotoxic processes. However, the effect of chronic hyperkalemia, especially if it persists between the periods of dialysis, on the nerve conduction needs to be seen in longitudinal studies with serial NCS in children. There was no significant association between vitamin D levels and uremic neuropathy in our cohort. However, the mean value of vitamin D was low and mean parathormone levels were high in our cohort, indicating an underlying deficiency in these patients requiring supplementation.

The subclinical electrophysiological abnormalities may be seen in 60–100% of patients undergoing dialysis for CKD. However, no association of dialysis was seen with subclinical neuropathy in our cohort. On the other hand, Yoganathan et al. reported a significant association between the two, although the duration of dialysis had no significant effect. A study of 100 non-dialysis CKD patients between 18 and 65 years who had serum creatinine >2 mg/dL, showed that 64% of patients had symptomatic polyneuropathy, and an additional 6% had subclinical polyneuropathy. The same study showed an increasing prevalence of neuropathy with worsening renal function [serum creatinine 2–3.4 (35%), 3.5–4.9 (89%), and >5 mg/Dl (100%)]. Studies in adults have also shown a strong correlation of declining eGFR and worsening stage of CKD with peripheral neuropathy. Although our study was cross-sectional, no significant association was noted with serum urea, creatinine, and GFR in our cohort. A probable reason for this could be the small sample size in our study. Hence, prospective studies with larger sample sizes are needed in children to ascertain the effects of worsening GFR on the prevalence of electrophysiological abnormalities and subsequent clinical neuropathy. Although uremic polyneuropathy has been noted to be more common in men, the same inference could not be drawn for children as they have lesser comorbidities and lesser duration of CKD or dialysis.

In conclusion, the prevalence of subclinical neuropathy in children with CKD stage III and above is high and needs attention. Children with CKD should be screened with NCS.
atleast once a year to detect subclinical electrophysiological abnormalities and to identify early electrophysiological markers of symptomatic peripheral neuropathy later on in these children. As disease related factors are not the major risk factors, nutritional factors such as micronutrients and vitamins should be evaluated for probable risk factors in our population. The small number of patients and limited biochemical parameters assessed limited our study. The late responses and an electromyography could not be tested in our cases due to the technical constraints. A prospective study should be conducted to study the effects of clinical and biochemical parameters in the causation of uremic neuropathy in children.

### Financial support and sponsorship

Nil.

### Conflicts of interest

There are no conflicts of interest.

### References

1. Mambelli E, Barrella M, Facchini MG, Mancini E, Sicuso C, Bainotti S, et al. The prevalence of peripheral neuropathy in hemodialysis patients. Clin Nephrol 2012;77:468‑75.
2. Aggarwal HK, Sood S, Jain D, Kaverappa V, Yadav S. Evaluation of spectrum of peripheral neuropathy in predialysis patients with chronic kidney disease. Ren Fail 2013;35:1323‑9.
3. Krishnan AV, Kiernan MC. Neurological complications of chronic kidney disease. Nat Rev Neurol 2009;5:542‑51.
4. Levey AS, Eckardt K‑U, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: A position statement from Kidney disease: Improving global outcomes (KDIGO). Kidney Int 2005;67:2089‑100.
5. Yoganathan S, Bagga A, Gulati S, Toteja GS, Hari P, Sinha A, et al. Prevalence of electrophysiologically defined peripheral neuropathy in children with chronic kidney disease stage IV and V: A cross sectional study. Muscle Nerve 2018;57:792‑8.
6. Abd El Naby SA, Bahbah WA, Kasemy ZA, Mahmoud AA. Neurophysiological and neuroradiological changes in children with chronic kidney disease. Front Pediatr 2020;8:507008.
7. Elzouki A, Carroll J, Butinar D, Moosa A. Improved neurological outcome in children with chronic renal disease from infancy. Pediatr Nephrol 1994;8:205‑10.
8. Stevens PE, Levin A. Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group. Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013;158:825‑830.
9. Ouvrier RA, Wilmhurst JM. Overview of the Neuropathies. Philadelphia PA: Butterworth Heinemann Elsevier; 2003. p. 339‑59.
10. Mcmillan HJ, Ryan MM. Overview of Pediatric Peripheral Neuropathies. 2nd ed. USA: Academic Press; 2015. p. 274‑88.
11. Preston DC, Shapiro BE. Basic nerve conduction studies. In: Preston DC, Shapiro BE, editor. Electromyography and Neuromuscular Disorders. 3rd ed. Philadelphia PA: Butterworth Heinemann Elsevier; 2012. p. 51‑5.
12. Dyck PJ. Peripheral neuropathy. Changing concepts, differential diagnosis and classification. Med Clin North Am 1968;52:895‑908.
13. Dyck PJ, Kratz KM, Lehman KA, Kames J, Melton L3 3rd, O’Brien PC, et al. The Rochester diabetic neuropathy study: Design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 1991;41:799‑807.
14. Dyck PJ. Current concepts in neurology. The causes, classification, and treatment of peripheral neuropathy. N Engl J Med 1982;307:283‑6.
15. Kandil MR, Darwish ES, Khedr EM, Sabry MM, Abdulah MA. A community‑based epidemiological study of peripheral neuropathies in Assiut, Egypt. Neurol Res 2012;34:960‑6.
16. Said G. Uremic neuropathy. Handb Clin Neurol 2013;115:607‑12.
17. Arnold R, Pianta TJ, Issar T, Kirby A, Scales CMK, Kwai NCG, et al. Peripheral neuropathy: An important contributor to physical limitation and morbidity in stages 3 and 4 chronic kidney disease. Nephrol Dial Transplant 2022;37:713‑9.
18. Hamed SA. Neurologic conditions and disorders of uremic syndrome of chronic kidney disease: Presentations, causes, and treatment strategies. Expert Rev Clin Pharmacol 2019;12:61‑90.
19. de Beaufort CE, Andrê JL, Heimans JJ, van der Eerden HA, van Diemen NG, Duc ML, Pierson M. Peripheral nerve function in children with end‑stage renal failure. Pediatr Nephrol 1989;3:173‑8.
20. Dyck PJ, Johnson WJ, Lambert EH, O’Brien PC. Segmental demyelination secondary to axonal degeneration in uremic neuropathy. Mayo Clin Proc 1971;46:400‑31.
21. Bansal VK, Bansal S. Nervous system disorders in dialysis patients. Handb Clin Neurol 2014;119:395‑404.
22. Akronoson S, Kofron, K, Voipio‑Pulkki LM, Falck B. Neurophysiologic parameters and symptoms in chronic renal failure. Muscle Nerve 2002;25:884‑90.
23. Jasti DB, Mallipeddi S, Apparao A, Vengamma B, Sivakumar V, Kolli S. A clinical and electrophysiological study of peripheral neuropathies in predialysis chronic kidney disease patients and relation of severity of peripheral neuropathy with degree of renal failure. J Neurosci Rural Pract 2017;8:516‑24.